Candel Therapeutics to Present Promising Phase 3 Data at SITC's Annual Meeting
Candel Therapeutics, Inc. is set to make waves at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting. The company will present data from its phase 3 clinical trial of CAN-2409, led by Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, on November 7, 2025, in National Harbor, Maryland.
Candel's lead product candidate, CAN-2409, has shown promising results in clinical trials for non-small cell lung cancer (NSCLC) and prostate cancer. The company has successfully completed phase 2a trials in NSCLC and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 trial in prostate cancer. CAN-2409 aims to stimulate an individualized, systemic anti-tumor immune response in patients.
In addition to CAN-2409, Candel's HSV platform has another lead candidate, CAN-3110, currently in a phase 1b clinical trial for recurrent high-grade glioma. The company's enLIGHTEN Discovery Platform is a systematic approach to developing new viral immunotherapies for solid tumors. Candel's stock is publicly traded on the Nasdaq under the symbol CADL.
Candel Therapeutics will present two poster presentations at SITC's Annual Meeting, highlighting the company's progress in its fight against cancer. The meeting provides an opportunity for Candel to showcase its innovative platforms and clinical trial data, potentially impacting the future of cancer immunotherapy.
Read also:
- Capella Nursing Students Gear Up for Crucial FPX 4050 Assessments
- Comprehensive Overview of Addressing Traumatic Brain Injuries (TBIs)
- Enhanced Health Services Provisioned by San Diego Academic Health Partnership Continues During COVID-19 and Beyond
- Vaccination drive targeting infants under 6 months old against bronchiolitis in the region of Andalucia
